ExamFinch.com My Study

Study guide

11.2 Critical Tachyarrhythmias: Atrial Fibrillation with RVR, VT & VF

Practice this exam

ABIM Critical Care Medicine Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Orientation: Format, Blueprint & Study Strategy

1.1 ABIM Critical Care Medicine Exam: Format, Blueprint & Study Strategy

2 Chapter 2: Acute Respiratory Failure & ARDS

2.1 ARDS Definition, Pathophysiology & Phenotypes 2.2 Lung-Protective Mechanical Ventilation 2.3 Refractory ARDS: Prone Positioning, Neuromuscular Blockade & VV-ECMO

3 Chapter 3: Obstructive Airways, Pulmonary Vascular & Pleural Emergencies

3.1 Severe Asthma & COPD Exacerbations in the ICU 3.2 Massive & Submassive Pulmonary Embolism 3.3 Pulmonary Hypertension & Right Ventricular Failure in the ICU 3.4 Massive Hemoptysis, Complex Pleural Effusions & Thoracic Drainage

4 Chapter 4: Airway, Parenchymal & Nonthrombotic Pulmonary Emergencies

4.1 Airway Management, Upper-Airway Obstruction & Artificial-Airway Complications 4.2 Diffuse Alveolar Hemorrhage, Interstitial Lung Disease, Pulmonary Vasculitis & Noncardiogenic Edema 4.3 Severe Community-Acquired & Viral Pneumonia 4.4 Nonthrombotic Embolism (Air, Fat, Amniotic Fluid, Tumor, Septic) & Acute Chest Syndrome

5 Chapter 5: Mechanical Ventilation Modes, Dyssynchrony & Liberation

5.1 Mechanical Ventilator Modes & Advanced Breath Delivery 5.2 Patient-Ventilator Dyssynchrony & Waveform Analysis 5.3 Ventilator Liberation, Spontaneous Breathing Trials & Post-Extubation Support

6 Chapter 6: Shock Syndromes & Hemodynamic Principles

6.1 Shock Classification, Cellular Pathophysiology & Biomarkers 6.2 Hemodynamic Monitoring: Arterial Lines, CVP & Pulmonary Artery Catheter 6.3 Dynamic Assessment of Fluid Responsiveness & Resuscitation Targets

7 Chapter 7: Vasoactive Therapies & Mechanical Circulatory Support

7.1 Vasopressors & Inotropes: Pharmacology & Clinical Titration 7.2 Temporary Mechanical Circulatory Support: IABP, Impella & TandemHeart 7.3 Venoarterial ECMO (VA-ECMO) & Differential Hypoxemia 7.4 Post-Cardiac Arrest Care, Targeted Temperature Management & Neuroprognostication

8 Chapter 8: Acute Kidney Injury & Renal Replacement Therapy

8.1 KDIGO AKI Classification, Etiologies & Diagnostic Evaluation 8.2 Continuous Renal Replacement Therapy (CRRT) vs Intermittent Hemodialysis 8.3 Indications & Timing for RRT in Critical Illness: AKIKI & STARRT-AKI

9 Chapter 9: Electrolyte, Acid-Base & Endocrine Emergencies

9.1 Severe Dysnatremias: Hyponatremia, Hypernatremia & Osmotic Demyelination 9.2 Potassium, Calcium, Magnesium & Phosphate Disorders 9.3 Complex & Mixed Acid-Base Disorders: Boston vs Copenhagen vs Stewart 9.4 Endocrine Crises: DKA, HHS, Thyroid Storm, Myxedema Coma & Adrenal Crisis

10 Chapter 10: Glycemic Control, Hyperammonemia, Pituitary & Adrenal Disorders

10.1 ICU Glycemic Control & Severe Hypoglycemia 10.2 Non-Hepatic Hyperammonemia & Metabolic Encephalopathy 10.3 Pituitary Emergencies, Adrenal Excess & Critical Illness-Related Corticosteroid Insufficiency

11 Chapter 11: Acute Coronary Syndromes & Cardiac Arrhythmias

11.1 Acute Coronary Syndromes & Mechanical Complications of Myocardial Infarction 11.2 Critical Tachyarrhythmias: Atrial Fibrillation with RVR, VT & VF 11.3 Critical Bradyarrhythmias, Conduction Blocks & Temporary Cardiac Pacing

12 Chapter 12: Acute Heart Failure, Valvular & Pericardial Emergencies

12.1 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 12.2 Acute Valvular Regurgitation & Prosthetic Valve Emergencies 12.3 Pericardial Tamponade & Acute Aortic Syndromes

13 Chapter 13: Myocardial Disease, Hypertensive & Cardiac Device Emergencies

13.1 Fulminant Myocarditis, Stress & Peripartum Cardiomyopathy, and Hypertrophic Cardiomyopathy 13.2 Hypertensive Emergencies & Ruptured Abdominal Aortic Aneurysm 13.3 Implanted Cardiac Devices, LVAD Emergencies & Electrical Storm

14 Chapter 14: Sepsis & Systemic Infectious Diseases

14.1 Sepsis-3 Definitions & Surviving Sepsis Campaign 2026 Guidelines 14.2 Refractory Septic Shock & Adjunctive Therapies 14.3 Multidrug-Resistant Pathogens & Antimicrobial Stewardship in the ICU

15 Chapter 15: ICU-Acquired & Severe Focal Infections

15.1 Hospital-Acquired & Ventilator-Associated Pneumonia 15.2 Central Line-Associated Bloodstream Infections & Catheter-Associated UTIs 15.3 Intra-Abdominal Sepsis, Necrotizing Soft Tissue Infections & CNS Infections

16 Chapter 16: Focal, Special-Host & Systemic Infections

16.1 CNS Infections Beyond Bacterial Meningitis: Encephalitis, Brain Abscess & Epidural Abscess 16.2 Infections in the Immunocompromised Host, Tropical & Bioterror Infections 16.3 Infective Endocarditis, Device Infections & Other Focal Cardiovascular Infections 16.4 Antimicrobial Pharmacokinetics, Allergy, Toxicity & Infection Prevention 16.5 Gastrointestinal & Hepatobiliary Infections: Fulminant C. difficile, Typhlitis, CMV Colitis & Abscesses

17 Chapter 17: Neurocritical Care & Coma

17.1 Coma, Altered Mental Status & Acute Delirium in the ICU 17.2 Status Epilepticus & Non-Convulsive Status Epilepticus 17.3 Acute Ischemic Stroke & Intracranial Hemorrhage

18 Chapter 18: Cerebrovascular Syndromes, Encephalopathy & Withdrawal States

18.1 Cerebral Venous Sinus Thrombosis, PRES & Reversible Cerebral Vasoconstriction Syndrome 18.2 Alcohol & Sedative Withdrawal, Wernicke Encephalopathy & Drug-Induced Encephalopathy

19 Chapter 19: Intracranial Hypertension & Neuromuscular Weakness

19.1 Intracranial Pressure Monitoring, Cerebral Perfusion & Tiered ICP Management 19.2 Acute Neuromuscular Respiratory Failure, ICU-Acquired Weakness & Brain Death Determination

20 Chapter 20: Traumatic Brain Injury, Spinal Cord Injury & Toxin-Mediated Paralysis

20.1 Traumatic Brain Injury Management & Paroxysmal Sympathetic Hyperactivity 20.2 Acute Spinal Cord Injury, Neurogenic Shock & Autonomic Dysreflexia 20.3 Toxin-Mediated Paralysis & Neuromuscular Crises: Botulism, Tetanus, Tick Paralysis & Myasthenic Crisis

21 Chapter 21: Gastrointestinal, Hepatic & Abdominal Emergencies

21.1 Acute Upper & Lower Gastrointestinal Bleeding in the ICU 21.2 Acute Liver Failure & Severe Acute Pancreatitis 21.3 Abdominal Compartment Syndrome & Acute Mesenteric Ischemia

22 Chapter 22: Luminal GI Emergencies & Complications of Cirrhosis

22.1 Esophageal, Gastric & Bowel Emergencies: Perforation, Obstruction, Ogilvie Syndrome & Colonic Ischemia 22.2 Complications of Cirrhosis: Alcohol-Associated Hepatitis, Hepatorenal Syndrome & Pulmonary Vascular Syndromes

23 Chapter 23: Trauma, Burns & Perioperative Critical Care

23.1 Polytrauma Resuscitation, Damage Control & Massive Transfusion 23.2 Severe Burn Injury, Inhalation Injury & Environmental Emergencies 23.3 Perioperative Critical Care for High-Risk Surgical Patients

24 Chapter 24: Thoracic Trauma, Environmental Injury & Obstetric Critical Care

24.1 Thoracic Trauma: Flail Chest, Pulmonary Contusion, Great Vessel & Tracheobronchial Injury 24.2 Environmental Injury: Drowning, Diving, Altitude, Heat, Cold, Electrical & Radiation 24.3 Obstetric & Genitourinary Emergencies and the Physiology of Pregnancy

25 Chapter 25: Transplantation, Donor Management & Post-Cardiac Surgery Care

25.1 Solid Organ Transplant Recipients & Deceased Donor Management 25.2 Post-Cardiac Surgery Critical Care: Bleeding, Tamponade, Low Output & Vasoplegia

26 Chapter 26: Hematologic Emergencies, Toxicology, Critical Ultrasound & ICU Liberation

26.1 Hematologic Emergencies in the ICU: HIT, DIC, TMA & Anticoagulant Reversal 26.2 Critical Care Toxicology, Toxidromes & Specific Antidotes 26.3 Critical Care Point-of-Care Ultrasound (POCUS) 26.4 ICU Liberation, Analgosedation, Goals of Care & Critical Care Ethics

27 Chapter 27: Transfusion Medicine, Hematologic & Oncologic Disorders

27.1 Transfusion Medicine: Products, Thresholds, Reactions & Apheresis 27.2 Red and White Cell Disorders, Hemoglobinopathies, Factor Deficiencies & Hypercoagulable States 27.3 Oncologic Emergencies, Hematopoietic Cell Transplant Complications & Cellular Therapy Toxicity

28 Chapter 28: Clinical Pharmacology, Adverse Drug Reactions & Specific Poisonings

28.1 Pharmacokinetic Principles, Dose Adjustment & Drug Interactions in Critical Illness 28.2 Adverse Drug Reactions: Anaphylaxis, Severe Cutaneous Reactions & Hyperthermic Syndromes 28.3 Specific Poisonings: Sodium-Channel Blockers, Lithium, Valproate, Theophylline, Iron, Sulfonylureas & Methemoglobinemia

29 Chapter 29: Ethics, Research Methods, Administration & Abdominal Ultrasound

29.1 Advance Care Planning, Nonbeneficial Treatment, Informed Consent & Confidentiality 29.2 Critical Care Research Methods, Statistics, IRB Oversight & Quality Improvement 29.3 Abdominal, Vascular & Procedural Point-of-Care Ultrasound

11.2 Critical Tachyarrhythmias: Atrial Fibrillation with RVR, VT & VF

Key Takeaways Explain This Topic AI

Any tachyarrhythmia associated with acute hemodynamic instability (hypotension/shock, ischemic chest pain, altered mental status, or flash pulmonary edema) mandates immediate synchronized electrical cardioversion, synchronized to the R-wave to avoid the R-on-T phenomenon and ventricular fibrillation; pulseless VT and VF require immediate high-energy unsynchronized defibrillation.

New-onset Atrial Fibrillation with Rapid Ventricular Response (RVR) in the ICU is predominantly a secondary manifestation of reversible physiological triggers (sepsis, metabolic acidosis, hypokalemia, hypomagnesemia, sympathetic overstimulation, intravascular volume overload, acute respiratory failure); management requires aggressively correcting underlying triggers while titrating rate control.

For acute rate control in AF with RVR, intravenous beta-blockers (esmolol or metoprolol) are first-line in hyperadrenergic states with preserved ejection fraction; intravenous calcium channel blockers (diltiazem) are highly effective in preserved EF but strictly contraindicated in decompensated heart failure with reduced ejection fraction (HFrEF); intravenous amiodarone is the agent of choice in severe LV systolic dysfunction or borderline hypotension.

Polymorphic Ventricular Tachycardia with a prolonged baseline QTc (> 500 ms) represents Torsades de Pointes (TdP); first-line emergency management comprises intravenous magnesium sulfate (2 g bolus), immediate cessation of all QT-prolonging medications, and heart rate acceleration to shorten the QT interval via temporary transvenous overdrive pacing (90-110 bpm) or isoproterenol infusion, while Class Ia (procainamide) and Class III (amiodarone) antiarrhythmics are strictly contraindicated.

Last updated: October 2026

Emergency Triage of Critical Tachyarrhythmias

Tachyarrhythmias (heart rate > 100 bpm > 100\text{ bpm} > 100 bpm , typically clinically significant when > 150 bpm > 150\text{ bpm} > 150 bpm ) frequently precipitate or accelerate cardiorespiratory failure in the intensive care unit. The initial evaluation requires immediate parallel assessment of hemodynamic stability, QRS complex duration (narrow < 120 ms < 120\text{ ms} < 120 ms vs. wide ≥ 120 ms \ge 120\text{ ms} ≥ 120 ms ), and rhythm regularity.

Hemodynamic Instability and Electrical Cardioversion

A patient is classified as hemodynamically unstable when the tachyarrhythmia produces any of the following four critical manifestations:

Systemic Hypotension / Shock : Mean arterial pressure < 65 mmHg < 65\text{ mmHg} < 65 mmHg , systolic blood pressure < 90 mmHg < 90\text{ mmHg} < 90 mmHg , or clinical signs of hypoperfusion (cool clammy extremities, oliguria, worsening lactic acidosis).

Acute Altered Mental Status : Agitation, confusion, lethargy, or syncope resulting from cerebral hypoperfusion.

Ischemic Chest Discomfort : Ongoing angina or ECG evidence of acute myocardial ischemia (ST elevations or horizontal/downsloping ST depressions).

Acute Pulmonary Edema : Flash pulmonary congestion with respiratory distress, rales, and hypoxemia. TACHYARRHYTHMIA ASSESSMENT (HR > 150 BPM)

  • │
  • ┌───────────────────┴───────────────────┐
  • ▼ ▼
  • UNSTABLE PATIENT STABLE PATIENT
  • Hypotension / Shock • Differentiate QRS width:
  • Altered mental status - Narrow (< 120 ms)
  • Ischemic chest pain - Wide (>= 120 ms)
  • Flash pulmonary edema • Regular vs. Irregular
  • │ │
  • ▼ ▼
  • IMMEDIATE SYNCHRONIZED TARGETED PHARMACOTHERAPY
  • CARDIOVERSION (Biphasic) • AF/Flutter: Esmolol, Diltiazem,
  • AF: 120-200 J Amiodarone
  • Flutter / PSVT: 50-100 J • Monomorphic VT: Procainamide,
  • Monomorphic VT: 100 J Amiodarone
  • Pulseless VT / VF: • Torsades de Pointes: IV MgSO4,
  • UNSYNCHRONIZED DEFIBRILLATION Overdrive pacing, Isoproterenol
  • Synchronized Electrical Cardioversion Technique

For any unstable tachyarrhythmia with a pulse, immediate synchronized electrical cardioversion is mandatory:

Synchronization Mechanism : The defibrillator detects the peak of the intrinsic R-wave of the QRS complex and delivers energy exclusively during ventricular depolarization. This avoids delivering an electrical shock during the vulnerable period of repolarization (the upslope and peak of the T-wave), preventing the catastrophic R-on-T phenomenon that induces refractory ventricular fibrillation.

Recommended Energy Levels (Biphasic) :

Atrial Fibrillation : 120 – 200 J 120\text{--}200\text{ J} 120 – 200 J biphasic (or 200 J 200\text{ J} 200 J monophasic).

Atrial Flutter and Paroxysmal Supraventricular Tachycardia (PSVT) : 50 – 100 J 50\text{--}100\text{ J} 50 – 100 J biphasic.

Monomorphic Ventricular Tachycardia with a pulse : 100 J 100\text{ J} 100 J biphasic.

Pulseless VT and Ventricular Fibrillation (VF) : In pulseless arrest, the machine cannot identify or synchronize to an R-wave. Immediate high-energy unsynchronized defibrillation ( 120 – 200 J 120\text{--}200\text{ J} 120 – 200 J biphasic, 360 J 360\text{ J} 360 J monophasic) is administered immediately, followed by high-quality chest compressions and the standard ACLS cardiac arrest protocol.

Note

Prior to synchronized cardioversion in a conscious unstable patient, administer rapid-acting procedural sedation and analgesia (e.g., intravenous etomidate 0.15 – 0.2 mg/kg 0.15\text{--}0.2\text{ mg/kg} 0.15 – 0.2 mg/kg or midazolam 2 – 4 mg 2\text{--}4\text{ mg} 2 – 4 mg plus fentanyl 50 μ g 50\mu\text{g} 50 μ g ) whenever clinical stability allows, but never delay emergency cardioversion for a decompensating patient.

Atrial Fibrillation with Rapid Ventricular Response (RVR)

New-onset atrial fibrillation with RVR occurs in up to 30 % 30\% 30% of critically ill patients. It is characterized by chaotic, irregular fibrillatory baseline waves without discernible P waves and an irregularly irregular ventricular response, frequently exceeding 140 – 180 bpm 140\text{--}180\text{ bpm} 140 – 180 bpm . Loss of the coordinated atrial booster pump ("atrial kick") reduces left ventricular filling by 20 % to 30 % 20\%\text{ to }30\% 20% to 30% , which, combined with shortened diastolic filling time at high ventricular rates, precipitates acute hemodynamic deterioration.

Precipitating Triggers in the Intensive Care Unit

In the vast majority of ICU admissions, AF with RVR is a secondary manifestation of underlying physiological stress rather than an isolated primary cardiac event. Critical care clinicians must systematically evaluate for:

Systemic Inflammation & Infection : Severe sepsis, septic shock, pneumonia, SIRS, and bacteremia.

Electrolyte Derangements : Severe hypokalemia ( K + < 4.0 mEq/L K^+ < 4.0\text{ mEq/L} K + < 4.0 mEq/L ) and hypomagnesemia ( M g 2 + < 2.0 mg/dL Mg^{2+} < 2.0\text{ mg/dL} M g 2 + < 2.0 mg/dL ).

Catecholamine Surges : Endogenous pain, agitation, withdrawal, or exogenous vasopressor/inotropic infusions (norepinephrine, epinephrine, dopamine).

Intravascular Volume Shifts : Hypervolemia causing acute atrial stretch, or severe hypovolemia provoking compensatory neurohumoral activation.

Cardiopulmonary Pathologies : Acute pulmonary embolism, severe hypoxemia, acute hypercapnic respiratory failure, pericarditis, and recent cardiothoracic surgery.

Tip

Antiarrhythmic drugs and cardioversion will fail repeatedly if the underlying physiological driver is neglected. Always aggressively treat sepsis, correct potassium to > 4.0 mEq/L > 4.0\text{ mEq/L} > 4.0 mEq/L , replete magnesium to > 2.0 mg/dL > 2.0\text{ mg/dL} > 2.0 mg/dL , optimize intravascular volume, and minimize exogenous catecholamines while pursuing rate control.

Rate Control Pharmacotherapy in the ICU

When the patient is hemodynamically stable, pharmacotherapy is titrated toward a lenient resting heart rate target of < 110 bpm < 110\text{ bpm} < 110 bpm :

Intravenous Beta-Adrenergic Blockers :

Esmolol : An ultra-short-acting, cardioselective β 1 \beta_1 β 1 ​ -receptor antagonist. Administer an optional loading bolus of 500 μ g/kg 500\mu\text{g/kg} 500 μ g/kg over 1 minute, followed by a continuous infusion of 50 μ g/kg/min 50\mu\text{g/kg/min} 50 μ g/kg/min , titrated every 5 to 10 minutes by increments of 50 μ g/kg/min 50\mu\text{g/kg/min} 50 μ g/kg/min up to a maximum of 200 – 300 μ g/kg/min 200\text{--}300\mu\text{g/kg/min} 200 – 300 μ g/kg/min .

ICU Advantage : Rapid onset ( < 2 minutes < 2\text{ minutes} < 2 minutes ) and ultra-short elimination half-life ( 9 minutes 9\text{ minutes} 9 minutes ). If drug-induced hypotension or heart failure occurs, stopping the infusion results in complete hemodynamic recovery within 15 to 30 minutes.

Metoprolol Tartrate : 2.5 – 5.0 mg 2.5\text{--}5.0\text{ mg} 2.5 – 5.0 mg slow IV push over 2 minutes, repeated every 5 minutes up to a maximum cumulative dose of 15 mg 15\text{ mg} 15 mg .

Contraindications : Acute decompensated heart failure with reduced ejection fraction (HFrEF), severe bronchospasm, or cardiogenic shock.

Non-Dihydropyridine Calcium Channel Blockers :

Diltiazem : Highly potent AV-nodal blocking agent. Administer an initial bolus of 0.25 mg/kg 0.25\text{ mg/kg} 0.25 mg/kg (typically 15 – 20 mg 15\text{--}20\text{ mg} 15 – 20 mg ) IV over 2 minutes; if rate response is inadequate after 15 minutes, deliver a second bolus of 0.35 mg/kg 0.35\text{ mg/kg} 0.35 mg/kg (typically 20 – 25 mg 20\text{--}25\text{ mg} 20 – 25 mg ), followed by a continuous infusion of 5 – 15 mg/hr 5\text{--}15\text{ mg/hr} 5 – 15 mg/hr .

Strict Contraindications : Decompensated heart failure with reduced ejection fraction ( LVEF < 40 % \text{LVEF} < 40\% LVEF < 40% ) due to potent negative inotropic properties that trigger pulmonary edema and cardiogenic shock. Strictly contraindicated in pre-excited atrial fibrillation (Wolff-Parkinson-White syndrome), where AV nodal blockade diverts rapid impulses down the accessory pathway, degenerating into VF.

Intravenous Amiodarone :

Agent of Choice in Structural Heart Disease / HFrEF : Amiodarone is the safest and most effective agent for rate and rhythm control in patients with severe left ventricular systolic dysfunction ( LVEF < 40 % \text{LVEF} < 40\% LVEF < 40% ), active myocardial ischemia, or borderline hypotension.

Dosing : 150 mg 150\text{ mg} 150 mg IV diluted in 100 mL 100\text{ mL} 100 mL D 5 W D_5W D 5 ​ W infused over 10 minutes, followed by a continuous infusion of 1.0 mg/min 1.0\text{ mg/min} 1.0 mg/min for 6 hours ( 360 mg 360\text{ mg} 360 mg ), then 0.5 mg/min 0.5\text{ mg/min} 0.5 mg/min for 18 hours ( 540 mg 540\text{ mg} 540 mg ); cumulative 24-hour dose ≈ 1000 mg \approx 1000\text{ mg} ≈ 1000 mg (max 2.2 g 2.2\text{ g} 2.2 g ). Supplemental 150 mg 150\text{ mg} 150 mg boluses can be delivered for breakthrough tachycardias.

Mechanism : Possesses class III potassium-channel blocking action alongside non-competitive β \beta β -blockade, calcium-channel blockade, and sodium-channel blockade. Slows AV nodal conduction without depressing LV inotropy.

Intravenous Digoxin :

Administer 0.25 – 0.5 mg 0.25\text{--}0.5\text{ mg} 0.25 – 0.5 mg IV loading dose, followed by 0.25 mg 0.25\text{ mg} 0.25 mg every 4 to 6 hours to a maximum of 1.0 mg 1.0\text{ mg} 1.0 mg over 24 hours.

Clinical Role : Relies on vagomimetic parasympathetic activation to slow AV nodal conduction. In the hyperadrenergic state of the ICU (high circulating catecholamines), digoxin as monotherapy is largely ineffective for acute rate control. It is utilized primarily as a safe, non-depressant adjunct in patients with HFrEF and shock who cannot tolerate beta-blockers or calcium channel blockers.

Anticoagulation Decisions in the Intensive Care Unit

Balancing thromboembolic stroke prevention against bleeding risk in the ICU requires nuanced clinical judgment:

Thromboembolic Risk : Assessed using the CHA 2 DS 2 -VASc \text{CHA}_2\text{DS}_2\text{-VASc} CHA 2 ​ DS 2 ​ -VASc score. However, critically ill patients often possess transient, unquantified hypercoagulability (septic endothelial activation).

Bleeding Risk : Intensive care patients frequently exhibit major bleeding risk factors: invasive lines, surgical wounds, active coagulopathy, thrombocytopenia, and acute renal failure.

Cardioversion Safety Threshold : If new-onset AF has been continuously present for > 48 hours > 48\text{ hours} > 48 hours (or if duration is unknown) , elective cardioversion carries a substantial risk of dislodging a left atrial appendage (LAA) thrombus. A transesophageal echocardiogram (TEE) is mandatory to definitively rule out LAA thrombus prior to cardioversion, accompanied by therapeutic anticoagulation.

Preferred Anticoagulant : Continuous intravenous unfractionated heparin (UFH) titrated to an aPTT of 50 – 70 seconds 50\text{--}70\text{ seconds} 50 – 70 seconds is strongly preferred over direct oral anticoagulants (DOACs) or low-molecular-weight heparin (LMWH) in the ICU due to its short elimination half-life ( 60 – 90 minutes 60\text{--}90\text{ minutes} 60 – 90 minutes ) and immediate reversibility with protamine sulfate if emergency invasive procedures or bleeding events occur.

Ventricular Tachycardia (VT) and Ventricular Fibrillation (VF)

Wide-complex tachycardias ( Q R S ≥ 120 ms QRS \ge 120\text{ ms} QRS ≥ 120 ms , rate > 100 bpm > 100\text{ bpm} > 100 bpm ) in the ICU represent Ventricular Tachycardia in > 80 % > 80\% > 80% of cases , especially in patients with prior myocardial infarction, coronary artery disease, or structural heart disease. Assuming a wide-complex tachycardia is SVT with aberrancy without proof is a lethal diagnostic error.

Electrocardiographic Clues Favoring VT

Atrioventricular (AV) Dissociation : Independent atrial (P wave) and ventricular (QRS) rates; pathognomonic for VT.

Fusion and Capture Beats (Dressler Beats) : Rare supraventricular impulses that conduct through the AV node and capture the ventricles either partially (fusion) or fully (capture) during wide-complex tachycardia.

Extreme Axis Deviation ("Northwest Axis") : Frontal plane QRS axis between − 90 ∘ -90^\circ − 9 0 ∘ and ± 180 ∘ \pm 180^\circ ± 18 0 ∘ (negative in leads I and aVF, positive in aVR).

Precordial Concordance : Entire precordial lead set ( V 1 to V 6 V_1\text{ to }V_6 V 1 ​ to V 6 ​ ) showing entirely positive or entirely negative QRS complexes without RS complexes.

QRS Width : Exceeding 140 ms 140\text{ ms} 140 ms with right bundle branch block (RBBB) morphology, or exceeding 160 ms 160\text{ ms} 160 ms with left bundle branch block (LBBB) morphology.

Monomorphic Ventricular Tachycardia Management

Monomorphic VT features a single, stable QRS morphology, originating from a fixed anatomical myocardial scar or re-entrant circuit:

Pulseless VT : High-energy unsynchronized defibrillation ( 120 – 200 J 120\text{--}200\text{ J} 120 – 200 J biphasic), CPR, and ACLS arrest protocol.

Unstable VT with Pulse : Immediate synchronized electrical cardioversion ( 100 J 100\text{ J} 100 J biphasic).

Stable Monomorphic VT with Pulse :

Intravenous Procainamide : Class Ia sodium channel blocker. Administer 20 – 50 mg/min 20\text{--}50\text{ mg/min} 20 – 50 mg/min continuous infusion until the arrhythmia is terminated, hypotension ensues, QRS widens by > 50 % > 50\% > 50% , or the maximum cumulative dose of 17 mg/kg 17\text{ mg/kg} 17 mg/kg is reached. In the randomized multicenter PROCAMIO trial , procainamide demonstrated significantly higher acute termination efficacy and fewer adverse cardiac events compared to intravenous amiodarone for stable monomorphic VT.

Intravenous Amiodarone : 150 mg 150\text{ mg} 150 mg IV infused over 10 minutes, repeated as necessary for recurrent VT, followed by 1.0 mg/min 1.0\text{ mg/min} 1.0 mg/min maintenance infusion.

Intravenous Lidocaine : Class Ib antiarrhythmic ( 1.0 – 1.5 mg/kg 1.0\text{--}1.5\text{ mg/kg} 1.0 – 1.5 mg/kg IV bolus, followed by 1 – 4 mg/min 1\text{--}4\text{ mg/min} 1 – 4 mg/min infusion). Highly effective for VT occurring in the setting of acute myocardial ischemia or infarction.

Polymorphic VT and Torsades de Pointes (TdP)

Polymorphic ventricular tachycardia is characterized by continuously shifting QRS morphology, amplitude, and electrical axis twisting around the isoelectric line at rates of 200 – 250 bpm 200\text{--}250\text{ bpm} 200 – 250 bpm . POLYMORPHIC VT DIFFERENTIATION

  • │
  • ┌──────────────────────────┴──────────────────────────┐
  • ▼ ▼
  • NORMAL BASELINE QTc (< 450 ms) PROLONGED BASELINE QTc (> 500 ms)
  • "Ischemia-Driven Polymorphic VT" "TORSADES DE POINTES (TdP)"
  • Etiology: Acute plaque rupture, • Etiology: Drug-induced, hypokalemia,
  • severe coronary hypoperfusion hypomagnesemia, severe bradycardia
  • Mechanism: Re-entry in ischemic tissue • Mechanism: Early afterdepolarizations (EADs)
  • Treatment: Immediate reperfusion, • Treatment: IV Magnesium Sulfate (2 g),
  • IV Beta-blockers, IV Lidocaine, Overdrive pacing (90-110 bpm), Isoproterenol
  • Defibrillation for arrest • CONTRAINDICATED: Amiodarone, Procainamide
  • Pathophysiological Distinction: Ischemia vs. Torsades de Pointes

The fundamental clinical imperative is evaluating the baseline corrected QT interval (QTc) :

Polymorphic VT with Normal Baseline QTc : Driven by acute myocardial ischemia or acute coronary occlusion. Repolarization duration is normal, but acute regional ischemic heterogeneity produces re-entry. Management centers on immediate coronary revascularization (primary PCI), intravenous beta-blockers, intravenous lidocaine, and defibrillation.

Polymorphic VT with Prolonged Baseline QTc ( > 500 ms > 500\text{ ms} > 500 ms ) : This is Torsades de Pointes (TdP) . Prolongation of phase 2 and phase 3 of the cardiac action potential allows reactivation of L-type calcium channels and sodium channels, generating early afterdepolarizations (EADs) during late repolarization. When an EAD reaches threshold potential, it triggers a premature ventricular contraction that falls on the prolonged T-wave, initiating self-sustaining twisting ventricular tachycardia.

Etiologies of Prolonged QTc and Torsades de Pointes in the ICU

Electrolyte Abnormalities : Severe hypokalemia ( K + < 4.0 mEq/L K^+ < 4.0\text{ mEq/L} K + < 4.0 mEq/L ), severe hypomagnesemia ( M g 2 + < 2.0 mg/dL Mg^{2+} < 2.0\text{ mg/dL} M g 2 + < 2.0 mg/dL ), and severe hypocalcemia.

QT-Prolonging Pharmacotherapy :

Antiarrhythmics : Class Ia (procainamide, quinidine, disopyramide), Class III (sotalol, dofetilide, ibutilide). (Note: Intravenous amiodarone prolongs the QTc significantly, but possesses a very low incidence of TdP due to uniform prolongation of repolarization and calcium channel blockade).

Psychotropic Agents : Haloperidol (especially intravenous), chlorpromazine, quetiapine, ziprasidone, citalopram, escitalopram.

Antimicrobials : Macrolides (azithromycin, erythromycin), fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin), azole antifungals (fluconazole, voriconazole).

Antiemetics : Ondansetron, droperidol, metoclopramide.

Others : Methadone, pentamidine, organophosphate poisoning.

Severe Bradycardia / High-Grade AV Block : Produces pause-dependent prolongation of repolarization, predisposing to characteristic "short-long-short" sequences that initiate TdP.

Emergent Management Protocol for Torsades de Pointes

Intravenous Magnesium Sulfate : First-line pharmacological therapy regardless of baseline serum magnesium concentration. Administer 2 g 2\text{ g} 2 g IV diluted in 50 – 100 mL 50\text{--}100\text{ mL} 50 – 100 mL D 5 W D_5W D 5 ​ W over about 5 to 15 minutes when a pulse is present; a faster push is reserved for pulseless torsades. If paroxysms recur, repeat with a second 2 g 2\text{ g} 2 g IV bolus 5 to 10 minutes later, followed by a continuous infusion of 2 – 4 mg/min 2\text{--}4\text{ mg/min} 2 – 4 mg/min . Magnesium suppresses EADs by blocking inward L-type calcium current.

Discontinue All QT-Prolonging Pharmacotherapy : Immediately halt all offending neuroleptics, antiemetics, antibiotics, and antiarrhythmics.

Accelerate Heart Rate to Shorten the QTc Interval :

Temporary Transvenous Overdrive Pacing : The most definitive and reliable therapy for recurrent, refractory TdP. Pacing at 90 – 110 bpm 90\text{--}110\text{ bpm} 90 – 110 bpm shortens phase 3 ventricular repolarization, eliminates pause-dependent triggers, and abolishes EADs.

Intravenous Isoproterenol Infusion : Pure β \beta β -adrenergic agonist ( 2 – 10 μ g/min 2\text{--}10\mu\text{g/min} 2 – 10 μ g/min ) titrated to accelerate baseline heart rate > 90 – 100 bpm > 90\text{--}100\text{ bpm} > 90 – 100 bpm as a pharmacological bridge when pacing is delayed. Contraindications : Congenital long QT syndrome or active myocardial ischemia.

Aggressive Electrolyte Repletion : Rapidly replenish serum potassium to high-normal levels ( 4.5 – 5.0 mEq/L 4.5\text{--}5.0\text{ mEq/L} 4.5 – 5.0 mEq/L ) and serum magnesium to > 2.5 mg/dL > 2.5\text{ mg/dL} > 2.5 mg/dL .

Unstable or Degenerating TdP : Immediate unsynchronized high-energy defibrillation ( 120 – 200 J 120\text{--}200\text{ J} 120 – 200 J biphasic). Synchronization cannot track polymorphic QRS amplitudes and will fail to deliver energy or deliver an inappropriately timed shock.

Warning

Strict Contraindication : Never administer Class Ia antiarrhythmics (procainamide) or Class III antiarrhythmics (amiodarone, sotalol) to a patient with Torsades de Pointes. These drugs further prolong the QTc interval, precipitating unremitting, fatal polymorphic ventricular tachycardia.

Arrhythmia Entity Hemodynamic Status First-Line Emergency Action Secondary / Pharmacological Options Absolute Cautions & Contraindications

AF with RVR Unstable (shock, edema, ischemia) Immediate synchronized cardioversion ( 120 – 200 J 120\text{--}200\text{ J} 120 – 200 J biphasic) IV amiodarone if cardioversion fails or arrhythmia recurs Never delay cardioversion; sedate briefly if time permits

AF with RVR Stable; Preserved EF ( LVEF ≥ 40 % \text{LVEF} \ge 40\% LVEF ≥ 40% ) IV Beta-blocker (Esmolol infusion or Metoprolol bolus) IV Diltiazem bolus and infusion; correct electrolytes Avoid CCBs if WPW pre-excitation is suspected; target rate < 110 bpm < 110\text{ bpm} < 110 bpm

AF with RVR Stable; Reduced EF ( LVEF < 40 % \text{LVEF} < 40\% LVEF < 40% ) Intravenous Amiodarone ( 150 mg 150\text{ mg} 150 mg load, then 1 mg/min 1\text{ mg/min} 1 mg/min ) IV Digoxin adjunct; correct underlying sepsis/acidosis Strictly avoid Diltiazem/Verapamil ; avoid high-dose beta-blockers in shock

Monomorphic VT Unstable (with pulse) Immediate synchronized cardioversion ( 100 J 100\text{ J} 100 J biphasic) IV Amiodarone or Procainamide after rhythm conversion Ensure pacer/defibrillator sync marker tracks the R-wave

Monomorphic VT Stable (with pulse) IV Procainamide ( 20 – 50 mg/min 20\text{--}50\text{ mg/min} 20 – 50 mg/min up to 17 mg/kg 17\text{ mg/kg} 17 mg/kg ) IV Amiodarone ( 150 mg 150\text{ mg} 150 mg load); IV Lidocaine for ischemia Stop procainamide if QRS widens > 50 % > 50\% > 50% or hypotension develops

Torsades de Pointes Unstable / Degenerating Immediate unsynchronized defibrillation ( 120 – 200 J 120\text{--}200\text{ J} 120 – 200 J biphasic) High-quality CPR, ACLS algorithm Do not attempt synchronized shock (cannot track polymorphic peaks)

Torsades de Pointes Stable / Intermittent Paroxysms Intravenous Magnesium Sulfate ( 2 g 2\text{ g} 2 g IV over about 5-15 min with a pulse) Overdrive transvenous pacing ( 90 – 110 bpm 90\text{--}110\text{ bpm} 90 – 110 bpm ); IV Isoproterenol Strictly avoid Amiodarone and Procainamide (worsens QTc prolongation)

  • Narrow-Complex and Pre-Excited Tachycardias
  • Regular Narrow-Complex Tachycardia (AVNRT, AVRT, Atrial Tachycardia)

Unstable : synchronized cardioversion.

Stable : try vagal maneuvers first (the modified Valsalva maneuver with passive leg raise works better than standard Valsalva). If that fails, give adenosine 6 mg 6\text{ mg} 6 mg rapid IV push with a saline flush, then 12 mg 12\text{ mg} 12 mg if needed. Use a reduced initial dose (about 3 mg 3\text{ mg} 3 mg ) through a central line, after heart transplantation, or with dipyridamole or carbamazepine. Theophylline and caffeine blunt the effect.

Adenosine terminates re-entry that uses the AV node (AVNRT, orthodromic AVRT). In atrial flutter or atrial tachycardia, transient AV block unmasks the atrial activity instead, which is diagnostic.

If adenosine fails or the rhythm recurs, IV diltiazem, verapamil, or a beta-blocker are next. Avoid nondihydropyridine calcium-channel blockers in decompensated systolic heart failure.

Multifocal Atrial Tachycardia (MAT)

At least three distinct P-wave morphologies, varying PR intervals, and an irregular rate above 100 bpm 100\text{ bpm} 100 bpm . It is classically seen with decompensated COPD, hypoxemia, theophylline, and electrolyte disturbance.

Treat the underlying lung disease, hypoxemia, hypokalemia, and hypomagnesemia . Rate control with diltiazem, verapamil, or a cardioselective beta-blocker can help. Cardioversion and antiarrhythmics are ineffective , because MAT is not re-entrant.

Atrial Flutter

Typical flutter shows sawtooth inferior-lead flutter waves at about 300 bpm 300\text{ bpm} 300 bpm , often with 2:1 conduction (a ventricular rate near 150 bpm 150\text{ bpm} 150 bpm ).

Rate control is harder than in atrial fibrillation. Synchronized cardioversion works at low energy, and catheter ablation of the cavotricuspid isthmus is highly effective. Stroke prevention follows atrial fibrillation rules.

Pre-Excited Atrial Fibrillation (Wolff-Parkinson-White)

An irregular, very fast, wide-complex rhythm with varying QRS morphology (rates can exceed 250 bpm 250\text{ bpm} 250 bpm ) in a young patient suggests atrial fibrillation conducting down an accessory pathway.

Avoid AV-nodal blockers : adenosine, beta-blockers, diltiazem, verapamil, digoxin, and IV amiodarone. Blocking the node can favor accessory-pathway conduction and precipitate ventricular fibrillation.

Unstable : synchronized cardioversion. Stable : IV procainamide (or ibutilide), then refer for accessory-pathway ablation.